Biostar Pharmaceuticals, Inc., the Xianyang-based manufacturer of an over-the-counter Hepatitis B medicine and other pharmaceutical products, has appointed Deyin "Bill" Chen as chief financial officer, effective July 1, 2010. Chen replaces Elaine Zhao.
Chen brings more than 13 years of multinational and Big 4 accounting experiences to Biostar. His expertise includes financial management, financing transactions, corporate governance and investor relations. Most recently, Chen was an independent advisor engaged in local RMB PE fundraising and providing M&A and PE advisory and due diligence services. Prior to that, Chen was a partner of Trenwith Securities LLC, where he was engaged in and executed cross-border equity financing for various Chinese companies. He was also a senior business advisor of Ernst & Young and a senior financial advisor of IBM Global Services. From 1997 to 2000, Chen was the CFO for China Operations of Ashland Inc. Chen graduated with a Bachelor's degree in Nuclear Physics from Fudan University, and Master of Science degree in Nuclear Engineering and Accountancy from University of Cincinnati. He also holds a MBA degree from York University.